ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2011 financial results and provided guidance for 2012.
For 2011, the Company anticipates total revenues of $270 to $275 million. With respect to 2011 net income, and before taking into account all potential adjustments related to the termination by Abbott of the co-development agreement for TRU-016, the Company anticipates net income of $20 to $24 million. These potential adjustments could include, among others, an impairment to goodwill and intangible assets to be recorded in 2011.
